Replimune Group, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on February 3, 2026, by Replimune Group, Inc. (REPL), a Delaware corporation. The filing primarily addresses a material amendment to the Company's existing Loan and Security Agreement and references the announcement of financial results for the third fiscal quarter ended December 31, 2025.
Key Financial Metrics and Debt Structure
The filing details significant modifications to the Company's debt facility with Hercules Capital, Inc. and other lenders. Specific financial metrics regarding revenue, profit, or cash flow for the quarter ended December 31, 2025, are not provided in the text of this 8-K; they are referenced only as being contained in a separate news release (Exhibit 99.1).
Debt Facility Amendments:
- Tranche 3: Increased from $30 million to $35 million; availability extended to June 15, 2026. The full $35 million was funded on January 29, 2026.
- Tranche 4: Decreased from $50 million to $30 million; availability extended to September 30, 2026, or 60 days post-approval milestone.
- Tranche 5: $50 million availability extended to December 31, 2027, or 60 days post-revenue milestone.
- Tranche 6: Increased from $25 million to $40 million.
- Interest Rate: Amended to the greater of 8.50% or Prime Rate plus 1.75%.
- Amortization Date: Extended from October 1, 2026, to October 1, 2027.
- Revenue Milestone Date: Extended to September 30, 2027.
Material Changes
The primary material change is the restructuring of the loan agreement to provide extended timelines for funding tranches and milestone achievements. The Company secured immediate liquidity through the funding of the increased third tranche ($35 million). The reduction in the fourth tranche amount and the extension of the amortization date indicate a strategic adjustment to the Company's capital deployment schedule.
Outlook, Risks, and Management Commentary
Management has extended key revenue and approval milestones, suggesting a revised timeline for product commercialization or regulatory approval. The extension of the amortization date to October 2027 provides additional runway before principal repayment obligations begin. The filing notes that the full text of the amendment will be filed as an exhibit to the 10-Q for the quarter ended December 31, 2025. No specific risks or contingencies are detailed in this text beyond the standard qualifications regarding the loan agreement terms.
Investor Verification Checklist
- Verify the specific revenue and cash burn figures for Q3 2025 in the referenced news release (Exhibit 99.1), as they are not included in this 8-K text.
- Confirm the current status of the "approval milestone" and "revenue milestone" to assess the likelihood of accessing Tranches 4, 5, and 6.
- Review the full text of the Third Amendment to the Loan and Security Agreement (to be filed in the 10-Q) for covenants and default provisions.
- Assess the impact of the increased interest rate (minimum 8.50%) on future interest expense and cash flow requirements.